




版權說明:本文檔由用戶提供并上傳,收益歸屬內容提供方,若內容存在侵權,請進行舉報或認領
文檔簡介
1、沙格列汀在腎功能不全型糖尿病有效性Objectives:EfficacyuTo evaluate efficacy of saxagliptin 2.5 mg compared with placebo by assessment of absolute change from baseline in HbA1c and FPGuTo assess the change from baseline in background antihyperglycemic therapy, including daily dose of existing therapy or the addition o
2、f new therapy (OAD therapy or insulin)FPG, fasting plasma glucose; HbA1c, glycated hemoglobin; LT, long-term; OAD, oral antidiabetic; ST, short-term.Objectives:SafetyuTo evaluate the safety and tolerability of saxagliptin 2.5 mg compared with placebo by assessment of: AEs Lab values, including estim
3、ated CrCl (Cockcroft-Gault), estimated GFR, and urinary albumin:creatine ratio ECG, vital signs, body weight, physical examination Doubling of serum creatine or progression to end-stage renal impairmentAE, adverse event; CrCl, creatinine clearance; ECG, electrocardiogram; GFR, glomerular filtration
4、rate. Study Design Stratified enrollment based on degree of renal impairment 69 Sites in 12 European countries and the United StatesPlacebo Lead-in ST Treatment PeriodPlacebo2.5 mg Saxagliptin once daily1:112 Weeks2 WeeksLT Treatment Period40 WeeksContinue allowed stable OAD and/or insulin therapyAd
5、justment of background OAD and/or insulin as neededReference: CSR Figure 1Selected Inclusion and Exclusion CriteriaInclusion CriteriauPatients with T2DM and renal impairment (documented history of CrCl 50 mL/min within 3 months prior to enrollment)Moderate impairment: CrCl 30 50 mL/min Severe impair
6、ment: CrCl 1.5x ULNuBilirubin 1.5x ULNuCK 3x ULNReference: CSR 5.1; CSR 5.3.1; CSP 3.3.2, CSP 3.3.3; CSP Amendment Number 1ALT, alanine transaminase; AST, aspartate aminotransferase; CK, creatine kinase; T2DM, type 2 diabetes mellitus; ULN, upper limit of normal.Subject Disposition:Randomized and tr
7、eated (N = 170)Saxagliptin 5 mg (n = 85)Completed ST period and continued to LT period (n = 61)Discontinued ST and LT (n = 43) AE (n=5) Death (n=3) Incorrect enrollment (n=2) No longer meets study criteria (n=16) Withdrew consent (n=17)Completed LT (n = 42)Moderate (n = 29)Severe (n = 7)End-stage (n
8、 = 6)Placebo (n = 85)Completed ST period and continued to LT period (n = 68)Discontinued ST and LT (n = 35) AE (n=2) Death (n=4) Incorrect enrollment (n=1) No longer meets study criteria (n=13) Other (n=1) Poor/non-compliance (n=4) Withdrew consent (n=10)Completed LT (n = 50) Moderate (n = 27) Sever
9、e (n = 14) End-stage (n = 9)aBefore randomization, total number enrolled=572 and total number excluded=402.Reference: CSR Figure 2Demographic and Baseline Characteristics: Randomized Analysis SetSAXA 2.5 mg (N = 85)PBO(N = 85)Total (N = 170)Age (years)Mean (SD)66.8 (8.3)66.2 (9.1)66.5 (8.7)Range42.0
10、 80.043.0 86.042.0 86.0GenderMale32 (37.6)41 (48.2)73 (42.9)Female53 (62.4)44 (51.8)97 (57.1)Weight (kg)Mean (SD)83.6 (15.7)82.2 (14.4)82.9 (15.1)Range52.0 132.052.0 115.052.0 132.0BMI (kg/m2)Mean (SD)31.2 (6.1)30.2 (6.8)30.7 (6.4)Range 20.8 56.418.6 74.418.6 74.4Renal impairment category, n (%)Mode
11、rate48 (56.5)42 (49.4)90 (52.9)Severe18 (21.2)23 (27.1)41 (24.1)End-stage19 (22.4)20 (23.5)39 (22.9)Reference: CSR Table 11N: number of subjects in each category.PBO, placebo; SAXA, saxagliptin; SD, standard deviation.Baseline Diabetes Characteristics: Randomized Analysis SetSAXA 2.5 mg (N = 85)PBO(
12、N = 85)Total (N = 170)Duration of T2DM (years)Mean (SD)15.1 (7.5)18.2 (8.5)16.7 (8.1)RangeDuration of T2DM categories (years), n (%) 5 years80 (94.1)81 (95.3)161 (94.7) 10 years61 (71.8)67 (78.8)128 (75.3)Baseline HbA1c (%)Mean (SD)8.5 (1.22)8.1 (1.08)8.3 (1.17)Range6.6 11.35.0 11.15.0 11.3Baseline
13、HbA1c categories, n (%) 8.0%34 (40.0)42 (49.4)76 (44.7) 8.0% 9.0%28 (32.9)25 (29.4)53 (31.2) 9.0%23 (27.1)17 (20.0)40 (23.5)FPG (mg/dL)Mean (SD)187.9 (70.4)168.6 (59.2)178.2 (65.5)Range49.0 418.061.8 355.049.0 418.0FPG categories, n (%) 126 mg/dL13 (15.3)21 (24.7)34 (20.0) 126 mg/dL 150 mg/dL13 (15.
14、3)8 (9.4)21 (12.4) 150 mg/dL 220 mg/dL33 (38.8)43 (50.6)76 (44.7) 220 mg/dL 300 mg/dL19 (22.4)9 (10.6)28 (16.5) 300 mg/dL5 (5.9)3 (3.5)8 (4.7)Reference: CSR Table 12HbA1c Change From Baseline to Week 52: LOCF, Full Analysis Set (2 of 2)Adjusted Mean Change FromBaseline HbA1c (%)p0.001 vs PBO.Referen
15、ce: Table 7.2.2bLT; Figure 7.2LTAdjusted Mean Change FromBaseline HbA1c (%)ModerateModerateSevereSevereEnd-stageEnd-stageHbA1c Change From Baseline to Week 52 by Renal Impairment Category: LOCF, Full Analysis Set (3 of 3)ST + LT PeriodMean Change From Baseline HbA1c: LOCF, Full Analysis SetReference
16、: Table 7.2.2dLT; Figure 7.20LTWeeks Mean Change From Baseline HbA1C (%) ST + LT PeriodFPG Change From Baseline to Week 52 by Renal Impairment Category: LOCF, Full Analysis Set (3 of 3)Reference: Table 7.2.1aLT; Figure 7.10LTAdjusted Mean Change FromBaseline FPG (mg/dL)ModerateModerateSevereSevereEn
17、d-stageEnd-stageAll SAXA vs PBO comparisons within each renal impairment category were not significant.ST + LT PeriodSummary of Efficacy Results:HbA1cuMean decrease in HbA1c after 52 weeks of treatment with saxagliptin 2.5 mg once daily was greater than after treatment with placebo (p0.001)uMean dec
18、reases in HbA1c after 52 weeks of treatment with saxagliptin were numerically greater compared with placebo in subjects with moderate or severe renal impairment; mean decreases in subjects with ESRD was comparable between the treatment groupsFPGuThere was a numerically larger reduction in mean fasti
19、ng glucose value after 52 weeks of treatment with saxagliptin 2.5 mg once daily compared with placebo in subjects with moderate or severe renal impairmentuA reduction in FPG was not consistently demonstrated in subjects with ESRDChange in Antihyperglycemic Medications: ST + LT Periodu39/164 (24%) of
20、 subjects in the full analysis set had changes in baseline insulin and/or OAD medication during the 52-week treatment period Saxagliptin: 20/81 (25%) subjects Placebo: 19/83 (23%) subjectsOverall Summary of Adverse Events: Safety Analysis Set AE categoryaSAXA 2.5 mg (N = 85)PBO (N = 85)n (%)n (%)At
21、least 1 AE64 (75.3)60 (70.6)At least 1 AE related to study medication9 (10.6)11 (12.9)Deaths3 (3.5)4 (4.7)At least 1 SAE23 (27.1)24 (28.2)At least 1 SAE related to study medication1 (1.2)2 (2.4)Discontinued study medication due to SAE6 (7.1)6 (7.1)Discontinued study medication due to AE10 (11.8)7 (8
22、.2)Reference: Table 8.1aLTaEvents of hypoglycemia are included in all categories.AE, adverse event; SAE, serious adverse event.ST + LT PeriodMost Common Adverse Events ( 2%) by SOCSOCSAXA 2.5 mg(N = 85)PBO(N = 85)n (%)n (%)Total number of subjects with an AEa54 (63.5)55 (64.7)Infections and infestat
23、ions20 (23.5)22 (25.9)General disorders and administration site conditions10 (11.8)13 (15.3)Vascular disorders10 (11.8)14 (16.5)Gastrointestinal disorders9 (10.6)16 (18.8)Metabolism and nutrition disorders9 (10.6)10 (11.8)Nervous system disorders9 (10.6)10 (11.8)Respiratory, thoracic, and mediastina
24、l disorders9 (10.6)3 (3.5)Skin and subcutaneous tissue disorders8 (9.4)6 (7.1)Cardiac disorders7 (8.2)7 (8.2)Injury, poisoning and procedural complications7 (8.2)7 (8.2)Investigations7 (8.2)9 (10.6)Musculoskeletal and connective tissue disorders6 (7.1)6 (7.1)Blood and lymphatic system disorders5 (5.
25、9)10 (11.8)Renal and urinary disorders4 (4.7)7 (8.2)Eye disorders3 (3.5)2 (2.4)Benign, malignant, and unspecified neoplasms (including cysts and polyps)2 (2.4)0Ear and labyrinth disorders02 (2.4)Reference: Table 8.1kLTaExcluding all events of hypoglycemia.SOC, system organ class.Summary of Deaths: S
26、afety Analysis SetPreferred termSAXA 2.5 mg(N = 85)PBO(N = 85)n (%)n (%)Total number of subjects with an event3 (3.5)4 (4.7)Cardiac arrest1 (1.2)0Cardiac failure01 (1.2)Sudden death1 (1.2)2 (2.4)Cerebrovascular accident1 (1.2)0Sepsis01 (1.2)Reference: Table 8.2aLTST + LT PeriodSAEs ( 2%) by SOC and
27、Preferred Term: Safety Analysis SetSOCSAE (preferred term)SAXA 2.5 mg(N = 85)PBO(N = 85)n (%)n (%)Total subjects with an event23 (27.1)24 (28.2)Infections and infestations6 (7.1)5 (5.9)Pneumonia2 (2.4)0Cardiac disorders4 (4.7)4 (4.7)Myocardial infarction2 (2.4)1 (1.2)Gastrointestinal disorders3 (3.5
28、)1 (1.2)Nervous system disorders3 (3.5)2 (2.4)Vascular disorders3 (3.5)5 (5.9)Eye disorders2 (2.4)0General disorders and administrative site conditions2 (2.4)3 (3.5)Investigations2 (2.4)0Renal and urinary disorders2 (2.4)2 (2.4)Respiratory, thoracic, and mediastinal disorders2 (2.4)0Metabolism and n
29、utrition disorders1 (1.2)5 (5.9)Hypoglycemia02 (2.4)Injury, poisoning, and procedural complications03 (3.5)Reference: Table 8.3aLTST + LT PeriodSummary of Hypoglycemic EventsTreatment groupMajor hypoglycemic eventMinor hypoglycemic eventEvents suggestive for hypoglycemiaNot classifiedTotalSAXA 2.5 m
30、g (N=85)Subjects, N (%)1 (1.2)20 (23.5)7 (8.2)4 (4.7)24 (28.2)Events, N (%)1 (0.8)107 (81.1)13 (9.8)11 (8.3)132 (100.0)PBO (N=85)Subjects, N (%)1 (1.2)18 (21.2)9 (10.6)3 (3.5)25 (29.4)Events, N (%)1 (1.1)66 (73.3)18 (20.0)5 (5.6)90 (100.0)Total (N=170)Subjects, N (%)2 (1.2)38 (22.4)16 (9.4)7 (4.1)49
31、 (28.8)Events, N (%)2 (0.9)173 (77.9)31 (14.0)16 (7.2)222 (100.0)uA total of 12 subjects experienced 25 confirmed hypoglycemic events SAXA 2.5 mg: 8 subjects (9.4%) reported 16 eventsPBO: 4 subjects (4.7%) reported 9 eventsST + LT PeriodSummary of Adverse Events of Interest During ST + LT Period: Sa
32、fety Analysis SetuProportion of subjects with predefined cardiovascular events was similar in the two groups: 5.9% in saxagliptin and 7.1% in placebouProportion of subjects with predefined skin disorders was 2.4% in each treatment groupuProportion of subjects with 1 AE in infections/infestations sys
33、tem organ class: 23.5% saxagliptin subjects, 25.9% placebo subjectsThe only opportunistic infection was oral fungal infection in one placebo subjectuLymphocytopenia (2 subjects), thrombocytopenia (1 subject), hypersensitivity (1 subject), pancreatitis (1 subject) and fracture (2 subjects) were only
34、reported in the placebo group ( by predefined terms)uNo localized edema by predefined lower level terms reportedReference: CSR 8.3.4; CSR 8.3.5; Appendix 8.1LTChanges From Baseline in Serum Creatinine in Subjects With Moderate or Severe Renal Impairment: Safety Analysis SetSerum creatinine (mg/dL)Mo
35、derateSevereSAXA 2.5 mg(N = 85)PBO(N = 85)SAXA 2.5 mg(N = 85)PBO(N = 85)Baselinen48421823Mean (SE)1.90 (0.067)1.95 (0.074)2.88 (0.157)3.04 (0.174)Week 12n37381520Mean (SE) change from baseline0.01 (0.051)0.01 (0.075)0.19 (0.192)0.20 (0.200)Week 28n34341116Mean (SE) change from baseline0.03 (0.064)0.
36、07 (0.074)0.17 (0.212)0.33 (0.199)Week 52n2524714Mean (SE) change from baseline0.20 (0.131)0.23 (0.126)0.30 (0.182)0.76 (0.319)ST + LT PeriodChange From Baseline in Body Weight, BMI, and Waist Circumference: LOCF, Safety Analysis SetSAXA 2.5 mg (N = 85)PBO(N = 85)Body weight (kg)n7882Baseline mean (
37、SE)84.1 (1.84)83.1 (1.58)Week 52 mean (SE)83.4 (1.71)83.0 (1.67)Mean change from baseline (SE)0.7 (0.48)0.1 (0.42)95% CI1.6, 0.30.9, 0.8BMI (kg/m2)n7882Baseline mean (SE)31.5 (0.72)30.5 (0.74)Week 52 mean (SE)31.2 (0.66)30.5 (0.74)Mean change from baseline (SE)0.3 (0.19)0 (0.16)95% CI0.6, 0.10.4, 0.
38、3Waist circumference (cm)n7276Baseline mean (SE)107.1 (1.59)106.8 (1.36)Week 52 mean (SE)106.8 (1.54)106.2 (1.43)Mean change from baseline (SE)0.3 (0.54)0.6 (0.50)95% CI1.4, 0.71.6, 0.3Reference: Table 8.10aLTST + LT PeriodSummary of Safety Results: ST + LT Period (1 of 2)uThe number of subjects exp
39、eriencing any AE, SAE, or discontinuations due to an AE or SAE were similar between the treatment groupsuThere were 3 deaths in the saxagliptin and 4 deaths in the placebo groupuThe number of subjects experiencing any cardiovascular-related AEs were low and similar between the treatment groupsuThere
40、 were few events of special interest and the incidence of these few events was similar in the saxagliptin compared with placebo treatment groupuThe number of subjects with marked abnormality of serum creatinine was not unexpected for this population given the severity of renal diseaseSummary of Safe
41、ty Results: ST + LT Period (2 of 2)uThe proportion of subjects with any hypoglycemia event was similar in the saxagliptin compared with placebo treatment (28.2% vs 29.4%)uThe proportion of subjects who had a minor hypoglycemia event with plasma glucose 20% change (increase or decrease) in prescribed
42、 daily dose Ten or fewer days of a change in antihyperglycemic medication was allowed Time to Study Discontinuation for Lack of Glycemic Control or Change in Dose or Type of Other Antihyperglycemic AgentsaST + LT PeriodReference: CSR Figure 40102030405060708090100BL46121820242832364044485256WeeksPer
43、centage of subjects (%)SAXA 2.5 mgPBONo. of subjects at risk8575695853524946383634333126085827870625855525046444141340SAXA 2.5 mgPBODataset: Safety analysis set.BL, baseline.Summary of Insulin Dose: LOCF, Full Analysis SetInsulin DoseSAXA 2.5 mg (N = 81)PBO(N = 83)na6755Baseline mean (SE)50.49 (3.91
44、8)41.47 (3.128)Week 12 mean (SE)nobservedb5347Mean change from baseline (SE)2.19 (3.265)5.42 (2.559)95% CI8.59, 4.210.40, 10.43Week 28 mean (SE)nobservedb4538Mean change from baseline (SE)7.07 (6.439)7.64 (2.637)95% CI5.55, 19.702.47, 12.81Week 52 mean (SE)nobservedb3324Mean change from baseline (SE
45、)0.18 (3.755)4.22 (2.394)95% CI7.18, 7.540.47. 8.91ST + LT PeriodaFull analysis set including LOCF; bNumber with observed values for the full analysis set.Summary of Exposure to Study Medications: Safety Analysis SetSAXA 2.5 mg (N = 85)PBO(N = 85)Exposure (weeks)Mean (SD)34.4 (20.23)39.2 (17.82)Rang
46、e0.3 54.02.1 53.3Exposure categories (weeks), n (%)0 1020 (23.5)8 (9.4)10 228 (9.4)12 (14.1)22 359 (10.6)8 (9.4)35 485 (5.9)6 (7.1)48 5443 (50.6)51 (60.0)Reference: Table 6.1aLTST + LT PeriodClassification of Hypoglycemic EventsuMajor: a symptomatic event requiring external assistance due to severe
47、impairment in consciousness or behavior, with plasma glucose 63 mg/dL and prompt recovery after glucose or glucagon administrationuMinor: either a symptomatic event, with plasma glucose 63 mg/dL and no need for external assistance, or an asymptomatic plasma glucose measurement 63 mg/dLuEvent suggest
48、ive for hypoglycemia: an event with symptoms associated with hypoglycemia, but no confirmatory plasma glucose measurementuConfirmed: an event with symptoms associated with hypoglycemia with a fingerstick glucose of 50 mg/dLHbA1c Change From Baseline to Week 52: LOCF, Full Analysis Set (1 of 2)HbA1c (%)SAXA 2.5 mg (N = 81)PBO(N = 83)n7882Baseline mean (SE)8.44 (0.134)8.10 (0.120)Week 52 mean (SE)7.41 (0.138)7.9
溫馨提示
- 1. 本站所有資源如無特殊說明,都需要本地電腦安裝OFFICE2007和PDF閱讀器。圖紙軟件為CAD,CAXA,PROE,UG,SolidWorks等.壓縮文件請下載最新的WinRAR軟件解壓。
- 2. 本站的文檔不包含任何第三方提供的附件圖紙等,如果需要附件,請聯系上傳者。文件的所有權益歸上傳用戶所有。
- 3. 本站RAR壓縮包中若帶圖紙,網頁內容里面會有圖紙預覽,若沒有圖紙預覽就沒有圖紙。
- 4. 未經權益所有人同意不得將文件中的內容挪作商業或盈利用途。
- 5. 人人文庫網僅提供信息存儲空間,僅對用戶上傳內容的表現方式做保護處理,對用戶上傳分享的文檔內容本身不做任何修改或編輯,并不能對任何下載內容負責。
- 6. 下載文件中如有侵權或不適當內容,請與我們聯系,我們立即糾正。
- 7. 本站不保證下載資源的準確性、安全性和完整性, 同時也不承擔用戶因使用這些下載資源對自己和他人造成任何形式的傷害或損失。
最新文檔
- GB/T 45820-2025石油煉化裝置用透平壓縮機
- TD/T 1043.2-2013暗管改良鹽堿地技術規程第2部分:規劃設計與施工
- 2025年伊索寓言讀后心得(8篇)
- 2025年初升高暑期數學講義專題01 數與式的計算重難點突破(含答案)
- 剝奪政治權利98課件
- 2025-2026年高校教師資格證之《高等教育法規》通關題庫附參考答案詳解(能力提升)
- 2025年江西省高速公路投資集團有限責任公司招聘筆試備考題庫附答案詳解(黃金題型)
- 2025年Z世代消費趨勢下新消費品牌品牌戰略研究報告
- 2025年K2學校STEM課程教學模式改革與效果分析報告
- 第三單元+明清時期(至鴉片戰爭前):統一多民族封建國家的鞏固與發展+綜合檢測課件-2024-2025學年度下學期七年級歷史期末復習
- 精裝分包勞務合同協議書
- 2025-2030中國酸奶冰淇淋市場需求前景預測及投資效益盈利性研究報告
- 2025年高考英語應用文第09講 讀后續寫分話題萬能結尾滿分句(講義)
- 2025年四年級下冊美術期末測試題附答案
- 圖像編輯基礎Photoshop試題及答案
- 新媒體國企面試題及答案
- 寶寶改姓夫妻協議書
- 宣城汽車精密零部件項目商業計劃書
- 2021入河(海)排污口三級排查技術指南
- 2024年深圳市中考歷史試卷真題(含答案解析)
- 高級病理學與病理學實驗技術知到智慧樹章節測試課后答案2024年秋浙江中醫藥大學
評論
0/150
提交評論